Patients will be screened for study eligibility during the Screening period within 3 weeks before Baseline (i.e., Day 1, the first day of Study Drug administration). Eligible patients, based on Screening assessments, will be randomly assigned to treatment with ATYR1940 or placebo. Patients who are randomized are considered to be enrolled in the study.